Celgene Corporation (CELG) Holdings Raised by Thompson Davis & CO. Inc.

Thompson Davis & CO. Inc. raised its stake in shares of Celgene Corporation (NASDAQ:CELG) by 5.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 773 shares of the biopharmaceutical company’s stock after acquiring an additional 43 shares during the period. Thompson Davis & CO. Inc.’s holdings in Celgene Corporation were worth $100,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Sowell Financial Services LLC increased its position in shares of Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 13 shares during the last quarter. South Texas Money Management Ltd. increased its position in shares of Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 15 shares during the last quarter. Flagship Harbor Advisors LLC increased its position in shares of Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 18 shares during the last quarter. Savant Capital LLC increased its position in shares of Celgene Corporation by 0.9% during the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 20 shares during the last quarter. Finally, Keel Point LLC increased its position in shares of Celgene Corporation by 0.9% during the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after acquiring an additional 28 shares during the last quarter. Institutional investors and hedge funds own 79.16% of the company’s stock.

Shares of Celgene Corporation (CELG) opened at $98.86 on Wednesday. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a market cap of $79,644.98, a price-to-earnings ratio of 15.81, a P/E/G ratio of 0.78 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. Celgene Corporation’s revenue for the quarter was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current year.

CELG has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and set a $151.00 price target for the company in a research report on Tuesday, July 18th. Robert W. Baird reiterated an “outperform” rating and set a $162.00 price target on shares of Celgene Corporation in a research report on Friday, July 21st. Mizuho set a $134.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. Finally, Cowen and Company reiterated an “outperform” rating and set a $150.00 price target on shares of Celgene Corporation in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. Celgene Corporation has an average rating of “Buy” and an average target price of $139.64.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/15/celgene-corporation-celg-holdings-raised-by-thompson-davis-co-inc.html.

In related news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the completion of the sale, the director now owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is owned by insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply